ES2173891T3 - Sistema de liberacion pulsatil de un farmaco multiparticulado. - Google Patents

Sistema de liberacion pulsatil de un farmaco multiparticulado.

Info

Publication number
ES2173891T3
ES2173891T3 ES93916656T ES93916656T ES2173891T3 ES 2173891 T3 ES2173891 T3 ES 2173891T3 ES 93916656 T ES93916656 T ES 93916656T ES 93916656 T ES93916656 T ES 93916656T ES 2173891 T3 ES2173891 T3 ES 2173891T3
Authority
ES
Spain
Prior art keywords
balls
water
dosage form
index
medicinal
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES93916656T
Other languages
English (en)
Inventor
Chih-Ming Chen
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Andrx Pharmaceuticals LLC
Original Assignee
Andrx Pharmaceuticals LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Andrx Pharmaceuticals LLC filed Critical Andrx Pharmaceuticals LLC
Application granted granted Critical
Publication of ES2173891T3 publication Critical patent/ES2173891T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5084—Mixtures of one or more drugs in different galenical forms, at least one of which being granules, microcapsules or (coated) microparticles according to A61K9/16 or A61K9/50, e.g. for obtaining a specific release pattern or for combining different drugs

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

UNA FORMA DE DOSIFICACION DE UNIDAD DE CAPSULA (4) O TABLETA COMPUESTA DE UN GRAN NUMERO DE BOLITAS (6,7,5) QUE COMPRENDEN DOS O MAS POBLACIONES DE BOLITAS/PARTICULAS. CADA BOLITA CONTIENE UN NUCLEO (3) QUE CONTIENE EL MEDICAMENTO TERAPEUTICO Y UN AGENTE OSMOTICO SOLUBLE EN AGUA, QUE ENCIERRAN UN POLIMERO INSOLUBLE EN AGUA. EL RECUBRIMIENTO DE PELICULA DE CADA POBLACION DE BOLITAS DIFIERE DE RECUBRIMIENTO DE CADA UNA DE LAS OTRAS POBLACIONES DE BOLITAS EN LA FORMA DE DOSIFICACION EN EL INDICE AL QUE EL AGUA PASA AL NUCLEO, Y EL INDICE AL QUE LA MEDICINA SE DIFUNDE FUERA DEL NUCLEO. EL AGENTE OSMOTICO SE DISUELVE EN EL AGUA, CUASANDO QUE LA BOLITA SE HINCHE Y REGULANDO EL INDICE DE DIFUSION DEL MEDICAMENTO EN EL INTERVALO DE USO. MIENTRAS CADA POBLACION DE BOLITAS LIBERA SECUENCIALMENTE SUS MEDICAMENTOS EN EL INTERVALO, EL EFECTO ES PROPORCIONA UNA SERIE DE ADMINISTRACIONES PULSATILES DE MEDICAMENTO CON UNA SOLA FORMA DE DOSIFICACION.
ES93916656T 1992-05-04 1993-06-03 Sistema de liberacion pulsatil de un farmaco multiparticulado. Expired - Lifetime ES2173891T3 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US07/878,416 US5260068A (en) 1992-05-04 1992-05-04 Multiparticulate pulsatile drug delivery system
PCT/US1993/005922 WO1994028882A1 (en) 1992-05-04 1993-06-03 Multiparticulate pulsatile drug delivery system

Publications (1)

Publication Number Publication Date
ES2173891T3 true ES2173891T3 (es) 2002-11-01

Family

ID=25371983

Family Applications (1)

Application Number Title Priority Date Filing Date
ES93916656T Expired - Lifetime ES2173891T3 (es) 1992-05-04 1993-06-03 Sistema de liberacion pulsatil de un farmaco multiparticulado.

Country Status (9)

Country Link
US (2) US5260068A (es)
EP (1) EP0701437B1 (es)
JP (1) JP3877329B2 (es)
AT (1) ATE215818T1 (es)
AU (1) AU680620B2 (es)
CA (1) CA2163433C (es)
DE (1) DE69331806T2 (es)
ES (1) ES2173891T3 (es)
WO (1) WO1994028882A1 (es)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8372225B2 (en) 2005-11-18 2013-02-12 Glaxo Group Limited Machine and method for pharmaceutical and pharmaceutical-like product assembly
US8858960B2 (en) 2004-11-19 2014-10-14 GlaxoSmithKline, LLC Method of producing a pharmaceutical product

Families Citing this family (249)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5302397A (en) * 1991-11-19 1994-04-12 Amsden Brian G Polymer-based drug delivery system
TW235239B (es) * 1992-11-20 1994-12-01 Pfizer
US5260069A (en) * 1992-11-27 1993-11-09 Anda Sr Pharmaceuticals Inc. Pulsatile particles drug delivery system
US5834024A (en) * 1995-01-05 1998-11-10 Fh Faulding & Co. Limited Controlled absorption diltiazem pharmaceutical formulation
US5567441A (en) * 1995-03-24 1996-10-22 Andrx Pharmaceuticals Inc. Diltiazem controlled release formulation
US5921285A (en) * 1995-09-28 1999-07-13 Fiberspar Spoolable Products, Inc. Composite spoolable tube
US8071128B2 (en) 1996-06-14 2011-12-06 Kyowa Hakko Kirin Co., Ltd. Intrabuccally rapidly disintegrating tablet and a production method of the tablets
AU7888298A (en) * 1997-01-03 1998-07-31 Elan Corporation, Plc Sustained release cisapride minitablet formulation
US5914134A (en) * 1997-01-27 1999-06-22 Wockhardt Europe Limited Process for the pulsatile delivery of diltiazem HCL and product produced thereby
US5788987A (en) * 1997-01-29 1998-08-04 Poli Industria Chimica Spa Methods for treating early morning pathologies
US5840329A (en) * 1997-05-15 1998-11-24 Bioadvances Llc Pulsatile drug delivery system
US20040029962A1 (en) * 1997-12-12 2004-02-12 Chih-Ming Chen HMG-COA reductase inhibitor extended release formulation
US8679534B2 (en) * 1997-12-12 2014-03-25 Andrx Labs, Llc HMG-CoA reductase inhibitor extended release formulation
CN1272785A (zh) * 1998-06-11 2000-11-08 Em工业股份有限公司 微渗透药物控释系统
EP1034538B1 (en) * 1998-06-12 2004-12-15 Koninklijke Philips Electronics N.V. Transferring compressed audio via a playback buffer
US6524620B2 (en) 1998-07-20 2003-02-25 Andrx Pharmaceuticals, Inc. Diltiazem controlled release formulation and method of manufacture
ATE321538T1 (de) * 1998-08-12 2006-04-15 Altana Pharma Ag Orale darreichungsform für pyridin-2- ylmethylsulfinyl-1h-benzimidazole
ES2237163T3 (es) * 1998-10-01 2005-07-16 Novartis Ag Nuevas formulaciones orales de revastigmina de liberacion controlada.
US20010055613A1 (en) * 1998-10-21 2001-12-27 Beth A. Burnside Oral pulsed dose drug delivery system
KR20070051953A (ko) * 1998-11-02 2007-05-18 엘란 코포레이션, 피엘씨 다입자 변형 방출 조성물
US20070122481A1 (en) * 1998-11-02 2007-05-31 Elan Corporation Plc Modified Release Compositions Comprising a Fluorocytidine Derivative for the Treatment of Cancer
US20090149479A1 (en) * 1998-11-02 2009-06-11 Elan Pharma International Limited Dosing regimen
US20090297597A1 (en) * 1998-11-02 2009-12-03 Gary Liversidge Modified Release Ticlopidine Compositions
US20080118556A1 (en) * 1998-11-02 2008-05-22 Elan Corporation, Plc Modified Release of Compositions Containing a Combination of Carbidopa, Levodopa and Entacapone
US20060240105A1 (en) * 1998-11-02 2006-10-26 Elan Corporation, Plc Multiparticulate modified release composition
US6270805B1 (en) 1998-11-06 2001-08-07 Andrx Pharmaceuticals, Inc. Two pellet controlled release formulation for water soluble drugs which contains an alkaline metal stearate
US8545880B2 (en) * 1999-02-26 2013-10-01 Andrx Pharmaceuticals, Llc Controlled release oral dosage form
US6210716B1 (en) * 1999-02-26 2001-04-03 Andrx Pharmaceuticals, Inc. Controlled release bupropion formulation
US20030170181A1 (en) * 1999-04-06 2003-09-11 Midha Kamal K. Method for preventing abuse of methylphenidate
EP1191924A4 (en) * 1999-04-06 2005-02-09 Pharmaquest Ltd PHARMACEUTICAL PHARMACEUTICAL FORM FOR PULSED ADMINISTRATION OF (D-THREO) METHYLPHENIDATE AND ANOTHER CNS STIMULATING SUBSTANCE
US6632451B2 (en) 1999-06-04 2003-10-14 Dexcel Pharma Technologies Ltd. Delayed total release two pulse gastrointestinal drug delivery system
US6428809B1 (en) * 1999-08-18 2002-08-06 Microdose Technologies, Inc. Metering and packaging of controlled release medication
US10179130B2 (en) 1999-10-29 2019-01-15 Purdue Pharma L.P. Controlled release hydrocodone formulations
HU230828B1 (en) 1999-10-29 2018-08-28 Euro Celtique Sa Controlled release hydrocodone formulations
US20060153914A1 (en) * 1999-12-10 2006-07-13 Biovail Laboratories International S.R.L. Chronotherapeutic diltiazem formulations and the administration thereof
US7108866B1 (en) 1999-12-10 2006-09-19 Biovall Laboratories International Srl Chronotherapeutic diltiazem formulations and the administration thereof
US6669954B2 (en) 2000-01-25 2003-12-30 John R. Crison Controlled release of drugs
JP2003521507A (ja) 2000-02-04 2003-07-15 ディポメド，インコーポレイティド ゼロ次薬物放出に接近するシェル−コア剤形
US6627223B2 (en) 2000-02-11 2003-09-30 Eurand Pharmaceuticals Ltd. Timed pulsatile drug delivery systems
US6632453B2 (en) 2000-02-24 2003-10-14 Advancis Pharmaceutical Corp. Ciprofoxacin-metronidazole antibiotic composition
US6991807B2 (en) * 2000-02-24 2006-01-31 Advancis Pharmaceutical, Corp. Antibiotic composition
US6730320B2 (en) 2000-02-24 2004-05-04 Advancis Pharmaceutical Corp. Tetracycline antibiotic product, use and formulation thereof
US6667057B2 (en) 2000-02-24 2003-12-23 Advancis Pharmaceutical Corp. Levofloxacin antibiotic product, use and formulation thereof
CA2400818C (en) * 2000-02-24 2009-01-06 Advancis Pharmaceutical Corporation Antibiotic and antifungal compositions
US6610328B2 (en) 2000-02-24 2003-08-26 Advancis Pharmaceutical Corp. Amoxicillin-clarithromycin antibiotic composition
US6565882B2 (en) 2000-02-24 2003-05-20 Advancis Pharmaceutical Corp Antibiotic composition with inhibitor
US6638532B2 (en) 2000-02-24 2003-10-28 Advancis Pharmaceutical Corp. Tetracycline—doxycycline antibiotic composition
CA2399856C (en) * 2000-02-24 2009-01-27 Edward M. Rudnic Antibiotic composition with inhibitor
US6544555B2 (en) 2000-02-24 2003-04-08 Advancis Pharmaceutical Corp. Antibiotic product, use and formulation thereof
US7025989B2 (en) * 2000-02-24 2006-04-11 Advancis Pharmaceutical Corp. Multiple-delayed released antibiotic product, use and formulation thereof
US6623758B2 (en) 2000-02-24 2003-09-23 Advancis Pharmaceutical Corp. Cephalosporin-metronidazole antibiotic composition
US6627222B2 (en) 2000-02-24 2003-09-30 Advancis Pharmaceutical Corp. Amoxicillin-dicloxacillin antibiotic composition
US6663891B2 (en) 2000-02-24 2003-12-16 Advancis Pharmaceutical Corp. Erythromyacin antibiotic product, use and formulation thereof
US6669948B2 (en) 2000-02-24 2003-12-30 Advancis Pharmaceutical Corp. Antibiotic product, use and formulation thereof
US6667042B2 (en) 2000-02-24 2003-12-23 Advancis Pharmaceutical Corp. Fluroquinilone antibiotic product, use and formulation thereof
US6663890B2 (en) 2000-02-24 2003-12-16 Advancis Pharmaceutical Corp. Metronidazole antibiotic product, use and formulation thereof
WO2001062229A1 (en) * 2000-02-24 2001-08-30 Advanced Pharma, Inc. Therapeutic product, use and formulation thereof
US6635277B2 (en) 2000-04-12 2003-10-21 Wockhardt Limited Composition for pulsatile delivery of diltiazem and process of manufacture
US6500457B1 (en) 2000-08-14 2002-12-31 Peirce Management, Llc Oral pharmaceutical dosage forms for pulsatile delivery of an antiarrhythmic agent
US7157095B2 (en) * 2000-10-13 2007-01-02 Advancis Pharmaceutical Corporation Multiple-delayed release antifungal product, use and formulation thereof
US6541014B2 (en) * 2000-10-13 2003-04-01 Advancis Pharmaceutical Corp. Antiviral product, use and formulation thereof
US7074417B2 (en) * 2000-10-13 2006-07-11 Advancis Pharmaceutical Corporation Multiple-delayed release anti-viral product, use and formulation thereof
US7105174B2 (en) * 2000-10-13 2006-09-12 Advancis Pharmaceutical Corporation Multiple-delayed release anti-neoplastic product, use and formulation thereof
CN101317825A (zh) 2000-10-30 2008-12-10 欧罗赛铁克股份有限公司 控释氢可酮制剂
US20020090388A1 (en) * 2000-12-01 2002-07-11 Humes H. David Intravascular drug delivery device and use therefor
US20020197314A1 (en) 2001-02-23 2002-12-26 Rudnic Edward M. Anti-fungal composition
US20070087048A1 (en) * 2001-05-31 2007-04-19 Abrams Andrew L Oral dosage combination pharmaceutical packaging
US6663896B1 (en) 2001-08-01 2003-12-16 Alvin S. Blum Delayed release aspirin for vascular obstruction prophylaxis
US20030083286A1 (en) * 2001-08-22 2003-05-01 Ching-Leou Teng Bioadhesive compositions and methods for enhanced intestinal drug absorption
US20030124196A1 (en) * 2001-08-22 2003-07-03 Susan Weinbach Pulsatile release compositions and methods for enhanced intestinal drug absorption
US20030050620A1 (en) * 2001-09-07 2003-03-13 Isa Odidi Combinatorial type controlled release drug delivery device
MXPA04002980A (es) * 2001-09-28 2005-06-20 Johnson & Johnson Formas de dosificacion que tienen un nucleo interior y coraza exterior con diferentes formas.
US6500454B1 (en) * 2001-10-04 2002-12-31 Eurand Pharmaceuticals Ltd. Timed, sustained release systems for propranolol
US9358214B2 (en) 2001-10-04 2016-06-07 Adare Pharmaceuticals, Inc. Timed, sustained release systems for propranolol
US20030152622A1 (en) * 2001-10-25 2003-08-14 Jenny Louie-Helm Formulation of an erodible, gastric retentive oral diuretic
US20030104052A1 (en) * 2001-10-25 2003-06-05 Bret Berner Gastric retentive oral dosage form with restricted drug release in the lower gastrointestinal tract
CA2409552A1 (en) 2001-10-25 2003-04-25 Depomed, Inc. Gastric retentive oral dosage form with restricted drug release in the lower gastrointestinal tract
US20030091630A1 (en) * 2001-10-25 2003-05-15 Jenny Louie-Helm Formulation of an erodible, gastric retentive oral dosage form using in vitro disintegration test data
US20050163846A1 (en) * 2001-11-21 2005-07-28 Eisai Co., Ltd. Preparation composition containing acid-unstable physiologically active compound, and process for producing same
US20050025824A1 (en) * 2001-12-14 2005-02-03 Eurand Pharmaceuticals Ltd. Pulsatile release histamine H2 antagonist dosage form
US6663888B2 (en) * 2001-12-14 2003-12-16 Eurand Pharmaceuticals Ltd. Pulsatile release histamine H2 antagonist dosage form
CA2478121A1 (en) * 2002-03-07 2003-09-18 Advancis Pharmaceutical Corporation Antibiotic composition
DE10214002A1 (de) * 2002-03-27 2003-10-09 Roehm Gmbh Pharmazeutische Formulierung für den Wirkstoff Budesonid
SE0201110D0 (sv) * 2002-04-12 2002-04-12 Astrazeneca Ab New film coating
US20030203027A1 (en) * 2002-04-26 2003-10-30 Ethicon, Inc. Coating technique for deposition of drug substance on a substrate
US6913768B2 (en) * 2002-09-24 2005-07-05 Shire Laboratories, Inc. Sustained release delivery of amphetamine salts
US20080220074A1 (en) * 2002-10-04 2008-09-11 Elan Corporation Plc Gamma radiation sterilized nanoparticulate docetaxel compositions and methods of making same
CA2771725C (en) 2002-10-16 2015-08-18 Takeda Pharmaceutical Company Limited Solid preparation comprising a non-toxic base and a proton pump inhibitor
CN1849142A (zh) 2002-11-15 2006-10-18 埃迪尼克斯(开曼)有限公司 2′－支链核苷和黄病毒突变
US6893660B2 (en) * 2002-11-21 2005-05-17 Andrx Pharmaceuticals, Inc. Stable pharmaceutical compositions without a stabilizer
US9107804B2 (en) 2002-12-10 2015-08-18 Nortec Development Associates, Inc. Method of preparing biologically active formulations
US20040114368A1 (en) * 2002-12-13 2004-06-17 Shyu Shing Jy Light device having rotatable or movable view
US8367111B2 (en) 2002-12-31 2013-02-05 Aptalis Pharmatech, Inc. Extended release dosage forms of propranolol hydrochloride
BRPI0408999A (pt) * 2003-04-04 2006-03-28 Pharmacia Corp comprimidos prensados de multiparticulados de liberação oral prolongada
CA2529984C (en) 2003-06-26 2012-09-25 Isa Odidi Oral multi-functional pharmaceutical capsule preparations of proton pump inhibitors
JP2006528190A (ja) * 2003-07-21 2006-12-14 アドバンシス ファーマスーティカル コーポレイション 抗生物質製剤、その使用法及び作成方法
JP2006528189A (ja) * 2003-07-21 2006-12-14 アドバンシス ファーマスーティカル コーポレイション 抗生物質産物、その使用法および製剤
JP2006528185A (ja) * 2003-07-21 2006-12-14 アドバンシス ファーマスーティカル コーポレイション 抗生物質製剤、その使用法及び作成方法
WO2005016311A1 (en) * 2003-08-11 2005-02-24 Advancis Pharmaceutical Corporation Robust pellet
CA2535398C (en) 2003-08-12 2013-11-12 Advancis Pharmaceuticals Corporation Antibiotic product, use and formulation thereof
CA2535780A1 (en) * 2003-08-29 2005-03-17 Advancis Pharmaceuticals Corporation Antibiotic product, use and formulation thereof
PL1667665T3 (pl) * 2003-09-03 2009-06-30 Pharmaton Sa Kapsułki zawierające peletki z substancją czynną z różnymi profilami uwalniania
JP2007513869A (ja) * 2003-09-15 2007-05-31 アドバンシス ファーマスーティカル コーポレイション 抗生物質製剤、その使用法及び作成方法
US20090304793A1 (en) * 2003-09-22 2009-12-10 Alpharma, Inc. Sustained release opioid formulations and methods of use
DE10353186A1 (de) * 2003-11-13 2005-06-16 Röhm GmbH & Co. KG Mehrschichtige Arzneiform, enthaltend eine in Bezug auf die Wirkstoffabgabe modulatorisch wirkende Substanz
DE10353196A1 (de) * 2003-11-13 2005-06-16 Röhm GmbH & Co. KG Mehrschichtige Arzneiform mit einer die Abgabe einer modulatorischen Substanz beeinflussenden Matrix
CA2550983C (en) * 2003-12-24 2013-09-17 Advancis Pharmaceutical Corporation Enhanced absorption of modified release dosage forms
MXPA06010785A (es) * 2004-03-26 2007-03-28 Eisai R&D Man Co Ltd Composicion farmaceutica de liberacion controlada y metodo para producir la misma.
US7404970B2 (en) * 2004-04-13 2008-07-29 Konec, Inc. Pain relief composition, method to form same, and method to use same
AU2005264864B2 (en) 2004-06-16 2011-08-11 Takeda Pharmaceutical Company Limited Multiple PPI dosage form
US20080280973A1 (en) * 2004-06-28 2008-11-13 Wender Paul A Laulimalide Analogues as Therapeutic Agents
US8394409B2 (en) * 2004-07-01 2013-03-12 Intellipharmaceutics Corp. Controlled extended drug release technology
JP2008505124A (ja) * 2004-07-02 2008-02-21 アドバンシス ファーマスーティカル コーポレイション パルス送達用錠剤
US10624858B2 (en) 2004-08-23 2020-04-21 Intellipharmaceutics Corp Controlled release composition using transition coating, and method of preparing same
US8747895B2 (en) 2004-09-13 2014-06-10 Aptalis Pharmatech, Inc. Orally disintegrating tablets of atomoxetine
US9884014B2 (en) 2004-10-12 2018-02-06 Adare Pharmaceuticals, Inc. Taste-masked pharmaceutical compositions
EP2417969A1 (en) 2004-10-21 2012-02-15 Aptalis Pharmatech, Inc. Taste-masked pharmaceutical compositions with gastrosoluble pore-formers
US20060105038A1 (en) * 2004-11-12 2006-05-18 Eurand Pharmaceuticals Limited Taste-masked pharmaceutical compositions prepared by coacervation
JP5258297B2 (ja) 2004-11-19 2013-08-07 グラクソスミスクライン・リミテッド・ライアビリティ・カンパニー 個人別に療法を合わせるために可変用量の薬物併用製品を特注で調剤する方法
WO2006063078A2 (en) * 2004-12-08 2006-06-15 Elan Corporation, Plc Topiramate pharmaceuticals composition
US20070298098A1 (en) * 2005-02-16 2007-12-27 Elan Pharma International Limited Controlled Release Compositions Comprising Levetiracetam
AU2006235483B2 (en) * 2005-04-12 2010-11-25 Elan Pharma International Limited Controlled release compositions comprising a cephalosporin for the treatment of a bacterial infection
US9161918B2 (en) 2005-05-02 2015-10-20 Adare Pharmaceuticals, Inc. Timed, pulsatile release systems
US20100136106A1 (en) * 2005-06-08 2010-06-03 Gary Liversidge Modified Release Famciclovir Compositions
EP1896002A4 (en) 2005-06-27 2009-11-25 Biovail Lab Int Srl BUPROPIONAL SALT FORMULATIONS WITH MODIFIED RELEASE
JP2009507774A (ja) * 2005-08-04 2009-02-26 アルザ・コーポレーシヨン 改良された性質を提供するポリマー混合物による半透過性膜を含んでなる浸透性用量形態物
US8778395B2 (en) 2005-08-11 2014-07-15 Andrx Labs, Llc Diltiazem controlled release formulation and method of manufacture
US8187639B2 (en) 2005-09-27 2012-05-29 Tissue Tech, Inc. Amniotic membrane preparations and purified compositions and anti-angiogenesis treatment
WO2007038686A2 (en) 2005-09-27 2007-04-05 Tissuetech, Inc. Amniotic membrane preparations and purified compositions and methods of use
WO2007037259A1 (ja) * 2005-09-29 2007-04-05 Eisai R & D Management Co., Ltd. 生体内での崩壊性を向上させたパルス製剤
WO2007053796A2 (en) * 2005-10-14 2007-05-10 Forest Laboratories, Inc. Methods of treating central nervous system disorders with a low dose combination of escitalopram and bupropion
CA2626025A1 (en) * 2005-10-14 2007-04-26 Forest Laboratories, Inc. Stable pharmaceutical formulations containing escitalopram and bupropion
NZ568700A (en) 2005-11-28 2012-03-30 Marinus Pharmaceuticals Solid stabilized particulate formulations comprising ganaxolone
US8778924B2 (en) * 2006-12-04 2014-07-15 Shionogi Inc. Modified release amoxicillin products
US8357394B2 (en) 2005-12-08 2013-01-22 Shionogi Inc. Compositions and methods for improved efficacy of penicillin-type antibiotics
US10064828B1 (en) 2005-12-23 2018-09-04 Intellipharmaceutics Corp. Pulsed extended-pulsed and extended-pulsed pulsed drug delivery systems
AU2007212110A1 (en) 2006-02-02 2007-08-16 Innovative Bio Therapies An extracorporeal cell-based therapeutic device and delivery system
US20070190141A1 (en) * 2006-02-16 2007-08-16 Aaron Dely Extended release opiate composition
US20090069275A1 (en) * 2006-02-17 2009-03-12 Rocca Jose G Low flush niacin formulation
US20070218126A1 (en) * 2006-03-16 2007-09-20 Tamer Laboratories, Inc. Compositions and Methods for Reducing Inflammation and Pain Associated with Acidosis
DK2018160T3 (da) 2006-03-16 2012-02-06 Tris Pharma Inc Modificeret depotformuleringer indeholdende lægemiddel-ionbytterharpikskomplekser
EP2007360B1 (en) * 2006-04-03 2014-11-26 Isa Odidi Controlled release delivery device comprising an organosol coat
US20070243250A1 (en) * 2006-04-17 2007-10-18 Actavis Group Ptc Hf Oral Dosage Formulations and Methods of Preparing the Same
US20070243245A1 (en) * 2006-04-17 2007-10-18 Actavis Group Ptc Hf Oral Dosage Formulations, Methods of Preparing the Same, and Methods of Reducing Food Effects on Drug Release
US8299052B2 (en) 2006-05-05 2012-10-30 Shionogi Inc. Pharmaceutical compositions and methods for improved bacterial eradication
US10960077B2 (en) 2006-05-12 2021-03-30 Intellipharmaceutics Corp. Abuse and alcohol resistant drug composition
ATE510538T1 (de) 2006-08-11 2011-06-15 Univ Johns Hopkins Zusammensetzungen und verfahren für nervenschutz
LT2530083T (lt) 2006-09-22 2016-09-26 Pharmacyclics Llc Brutono tirozinkinazės inhibitoriai
US20100105738A1 (en) * 2006-10-06 2010-04-29 Mitsuru Mizuno Extended release formulations of a proton pump inhibitor
BRPI0717721A2 (pt) 2006-11-28 2013-10-29 Marinus Pharmaceuticals "partículas complexadas de drogas, composição farmacêutica, uso de uma composição farmacêutica, partículas complexadas de droga estabilizadas no tamanho, método para a preparação de partículas estabilizadas da droga, composição farmacêutica sólida, comprimido oral ingerível e composição líquida em nanopartículas estabilizadas no tamanho"
WO2008068584A2 (en) * 2006-12-05 2008-06-12 University Of Witwatersrand, Johannesburg A heterogeneously configured multiparticulate gastrointestinal drug delivery system
AU2007340129B2 (en) 2006-12-26 2012-02-02 Pharmacyclics Llc Method of using histone deacetylase inhibitors and monitoring biomarkers in combination therapy
US20090004281A1 (en) * 2007-06-26 2009-01-01 Biovail Laboratories International S.R.L. Multiparticulate osmotic delivery system
EP2173329A1 (en) * 2007-07-03 2010-04-14 Synthon B.V. Tolterodine bead
MX2010002712A (es) 2007-09-10 2010-06-09 Calcimedica Inc Compuestos que modulan calcio intracelular.
US20090087483A1 (en) * 2007-09-27 2009-04-02 Sison Raymundo A Oral dosage combination pharmaceutical packaging
US8439033B2 (en) 2007-10-09 2013-05-14 Microdose Therapeutx, Inc. Inhalation device
RU2010119041A (ru) 2007-10-12 2011-11-20 Такеда Фармасьютикалз Норт Америка, Инк. (Us) Способы лечения нарушений желудочно-кишечного тракта, независимого от потребления пищи
US20090311335A1 (en) * 2008-06-12 2009-12-17 Scott Jenkins Combination of a triptan and an nsaid
AU2009327485A1 (en) 2008-06-18 2010-06-24 Cytopherx, Inc. Methods for propagation of renal precursor cells
EP2321303B1 (en) 2008-08-27 2019-11-27 Calcimedica, Inc. Compounds that modulate intracellular calcium
EP2344121B1 (en) * 2008-10-23 2017-07-12 Henkel IP & Holding GmbH Vaginal pellets comprising debranched starch
AU2009311877C1 (en) * 2008-11-07 2013-08-15 Samyang Holdings Corporation Pharmaceutical composition for release control of methylphenidate
WO2010071866A2 (en) 2008-12-19 2010-06-24 Nuon Therapeutics, Inc. Combination therapy for arthritis with tranilast
US20110311628A1 (en) 2009-03-09 2011-12-22 Council Of Scientific And Industrial Research Pulsatile release composition of therapeutic agent
US20100260859A1 (en) * 2009-04-09 2010-10-14 Elan Pharma International Limited Controlled-release clozapine compositions
US8603521B2 (en) 2009-04-17 2013-12-10 Pharmacyclics, Inc. Formulations of histone deacetylase inhibitor and uses thereof
EP2421901B1 (en) 2009-04-24 2015-10-28 Tissue Tech, Inc. Compositions containing hc ha complex and methods of use thereof
US7718662B1 (en) 2009-10-12 2010-05-18 Pharmacyclics, Inc. Pyrazolo-pyrimidine inhibitors of bruton's tyrosine kinase
CN102958515A (zh) 2009-12-02 2013-03-06 阿普塔利斯制药有限公司 非索非那定微胶囊及含有非索非那定微胶囊的组合物
CN105381524A (zh) 2010-01-05 2016-03-09 微剂量治疗技术公司 吸入设备和方法
US8475846B2 (en) * 2010-03-09 2013-07-02 Basf Corporation Colored micaceous pigments having bismuth oxychloride appearance and performance effects
EP2558866B1 (en) 2010-04-15 2016-08-17 Tracon Pharmaceuticals, Inc. Potentiation of anti-cancer activity through combination therapy with ber pathway inhibitors
CA2797533A1 (en) 2010-04-27 2011-11-10 Calcimedica, Inc. Compounds that modulate intracellular calcium
ES2591004T3 (es) 2010-04-27 2016-11-24 Calcimedica, Inc. Compuestos moduladores del calcio intracelular
US20130259875A1 (en) 2010-05-11 2013-10-03 Questcor Pharmaceuticals, Inc. Acth for treatment of amyotrophic lateral sclerosis
EP2609095A4 (en) 2010-08-27 2014-06-18 Calcimedica Inc COMPOUNDS MODULATING INTRACELLULAR CALCIUM
US8796416B1 (en) 2010-10-25 2014-08-05 Questcor Pharmaceuticals, Inc ACTH prophylactic treatment of renal disorders
US9603809B2 (en) 2011-03-23 2017-03-28 Ironshore Pharmaceuticals & Development, Inc. Methods of treatment of attention deficit hyperactivity disorder
WO2012129551A1 (en) 2011-03-23 2012-09-27 Ironshore Pharmaceuticals & Development, Inc. Methods and compositions for treatment of attention deficit disorder
US11241391B2 (en) 2011-03-23 2022-02-08 Ironshore Pharmaceuticals & Development, Inc. Compositions for treatment of attention deficit hyperactivity disorder
US9498447B2 (en) 2011-03-23 2016-11-22 Ironshore Pharmaceuticals & Development, Inc. Compositions for treatment of attention deficit hyperactivity disorder
US10292937B2 (en) 2011-03-23 2019-05-21 Ironshore Pharmaceuticals & Development, Inc. Methods of treatment of attention deficit hyperactivity disorder
US8927010B2 (en) 2011-03-23 2015-01-06 Ironshore Pharmaceuticals & Development, Inc. Compositions for treatment of attention deficit hyperactivity disorder
US8916588B2 (en) 2011-03-23 2014-12-23 Ironshore Pharmaceuticals & Development, Inc. Methods for treatment of attention deficit hyperactivity disorder
US10905652B2 (en) 2011-03-23 2021-02-02 Ironshore Pharmaceuticals & Development, Inc. Compositions for treatment of attention deficit hyperactivity disorder
US9283214B2 (en) 2011-03-23 2016-03-15 Ironshore Pharmaceuticals & Development, Inc. Compositions for treatment of attention deficit hyperactivity disorder
US9119809B2 (en) 2011-03-23 2015-09-01 Ironshore Pharmaceuticals & Development, Inc. Compositions for treatment of attention deficit hyperactivity disorder
US9526770B2 (en) 2011-04-28 2016-12-27 Tissuetech, Inc. Methods of modulating bone remodeling
EP2717888B1 (en) 2011-06-10 2020-09-09 Tissuetech, Inc. Methods of processing fetal support tissues
SG2014014419A (en) 2011-09-13 2014-07-30 Pharmacyclics Inc Formulations of histone deacetylase inhibitor in combination with bendamustine and uses thereof
EP2586429A1 (en) 2011-10-26 2013-05-01 Freund Pharmatec Ltd. Multi-unit drug delivery device for pulsatile or sustained release
EP2785184B1 (en) 2011-11-30 2020-06-10 Emory University Compositions comprising jak inhibitors and haart drugs for use in the prevention or treatment of hiv
US8377946B1 (en) 2011-12-30 2013-02-19 Pharmacyclics, Inc. Pyrazolo[3,4-d]pyrimidine and pyrrolo[2,3-d]pyrimidine compounds as kinase inhibitors
EP2620162A1 (de) 2012-01-27 2013-07-31 Life Science Inkubator Enzym-Polymer-Konjugat zur Endotoxin-Detoxifikation
DK3326611T3 (da) 2012-02-22 2020-08-17 Duchesnay Inc Formulering af doxylamin og pyridoxin og / eller metaboliter eller salt deraf
KR101378973B1 (ko) * 2012-04-13 2014-03-28 한미약품 주식회사 구형에 가까운 형태의 다중 투여 단위 정제를 포함하는 경질 캡슐 복합 제형 및 이의 제조방법
CN114652816A (zh) 2012-07-11 2022-06-24 组织技术公司 含有hc-ha/ptx3复合物的组合物及其使用方法
EP2884961B1 (en) 2012-08-15 2019-03-06 Tris Pharma Inc. Methylphenidate extended release chewable tablet
DK2900674T3 (en) 2012-09-28 2017-07-03 Univ Washington Through Its Center For Commercialization RELATIONSHIPS AND PROCEDURES FOR PREVENTION, TREATMENT AND / OR PROTECTION AGAINST SENSITIVE CELL DEATH
WO2014059333A1 (en) 2012-10-12 2014-04-17 Calcimedica, Inc. Compounds that modulate intracellular calcium
WO2014153221A2 (en) 2013-03-14 2014-09-25 Questcor Pharmaceuticals, Inc. Acth for treatment of acute respiratory distress syndrome
MY191347A (en) 2013-07-22 2022-06-17 Duchesnay Inc Composition for the management of nausea and vomiting
US9611263B2 (en) 2013-10-08 2017-04-04 Calcimedica, Inc. Compounds that modulate intracellular calcium
MX2016007111A (es) 2013-12-05 2016-08-11 Pharmacyclics Llc Inhibidores de tirosina quinasa de bruton.
US10570169B2 (en) 2014-05-22 2020-02-25 Ionis Pharmaceuticals, Inc. Conjugated antisense compounds and their use
TW201603818A (zh) 2014-06-03 2016-02-01 組織科技股份有限公司 組成物及方法
WO2016020901A1 (en) 2014-08-07 2016-02-11 Acerta Pharma B.V. Methods of treating cancers, immune and autoimmune diseases, and inflammatory diseases based on btk occupancy and btk resynthesis rate
US9839644B2 (en) 2014-09-09 2017-12-12 ARKAY Therapeutics, LLC Formulations and methods for treatment of metabolic syndrome
US9359316B1 (en) 2014-11-25 2016-06-07 Concentric Analgesics, Inc. Prodrugs of phenolic TRPV1 agonists
US10399994B2 (en) 2015-02-06 2019-09-03 University Of Washington Compounds and methods for preventing or treating sensory hair cell death
US10227333B2 (en) 2015-02-11 2019-03-12 Curtana Pharmaceuticals, Inc. Inhibition of OLIG2 activity
TW201642914A (zh) 2015-02-23 2016-12-16 組織科技股份有限公司 用於治療眼部疾病及失調的裝置及方法
CA2977521C (en) 2015-02-27 2024-03-19 Curtana Pharmaceuticals, Inc. 1-(aryl)-3-(heteroaryl) urea compounds and their use as olig2 inhibitors
CA2984443A1 (en) 2015-05-20 2016-11-24 Tissuetech, Inc. Compositions and methods for preventing the proliferation and epithelial-mesenchymal transition of epithelial cells
US11590228B1 (en) 2015-09-08 2023-02-28 Tris Pharma, Inc Extended release amphetamine compositions
US10780099B2 (en) 2015-10-16 2020-09-22 Marinus Pharmaceuticals, Inc. Injectable neurosteroid formulations containing nanoparticles
CN108778314A (zh) 2015-12-16 2018-11-09 沃尔特及伊莱萨霍尔医学研究院 Nk细胞中对细胞因子诱导的sh2蛋白的抑制
TW201733600A (zh) 2016-01-29 2017-10-01 帝聖工業公司 胎兒扶持組織物及使用方法
WO2017147146A1 (en) 2016-02-23 2017-08-31 Concentric Analgesics, Inc. Prodrugs of phenolic trpv1 agonists
JP2019516773A (ja) 2016-05-25 2019-06-20 コンセントリック アナルジジックス，インク． 改善された局所麻酔のための局所麻酔薬及び血管収縮薬と組み合わせたフェノールｔｒｐｖ１アゴニストのプロドラッグ
WO2017205766A1 (en) 2016-05-27 2017-11-30 Pharmacyclics Llc Inhibitors of interleukin-1 receptor-associated kinase
WO2017205762A1 (en) 2016-05-27 2017-11-30 Pharmacyclics Llc Inhibitors of interleukin-1 receptor-associated kinase
WO2017205769A1 (en) 2016-05-27 2017-11-30 Pharmacyclics Llc Inhibitors of interleukin-1 receptor-associated kinase
KR20230050474A (ko) 2016-08-11 2023-04-14 오비드 테라퓨틱스 인크. 간질 장애의 치료를 위한 방법 및 조성물
US11242323B2 (en) 2016-08-26 2022-02-08 Curtana Pharmaceuticals, Inc. Inhibition of OLIG2 activity
US10391105B2 (en) 2016-09-09 2019-08-27 Marinus Pharmaceuticals Inc. Methods of treating certain depressive disorders and delirium tremens
US11590081B1 (en) 2017-09-24 2023-02-28 Tris Pharma, Inc Extended release amphetamine tablets
US11319320B2 (en) 2017-11-06 2022-05-03 Snap Bio, Inc. PIM kinase inhibitor compositions, methods, and uses thereof
WO2019169112A1 (en) 2018-02-28 2019-09-06 Curtana Pharmaceuticals, Inc. Inhibition of olig2 activity
CN113166051A (zh) 2018-07-27 2021-07-23 同心镇痛药物公司 酚类trpv1激动剂的聚乙二醇化前药
US11266662B2 (en) 2018-12-07 2022-03-08 Marinus Pharmaceuticals, Inc. Ganaxolone for use in prophylaxis and treatment of postpartum depression
EP3906026A4 (en) 2018-12-31 2022-10-19 Biomea Fusion, LLC IRREVERSIBLE MENIN-MLL INTERACTION INHIBITORS
JP2022524243A (ja) 2019-03-15 2022-04-28 ユニサイシブ セラピューティクス インコーポレイテッド ニコランジル誘導体
JP2022543837A (ja) 2019-08-05 2022-10-14 マリナス ファーマシューティカルズ， インコーポレイテッド てんかん重積状態の治療に使用するためのガナキソロン
JP2023503928A (ja) 2019-12-06 2023-02-01 マリナス ファーマシューティカルズ， インコーポレイテッド 結節性硬化症の治療での使用のためのガナキソロン
US20240124467A1 (en) 2020-12-16 2024-04-18 Biomea Fusion, Inc. Fused pyrimidine compounds as inhibitors of menin-mll interaction
CA3204457A1 (en) 2021-01-06 2022-07-14 Ben SESSA Mdma in the treatment of alcohol use disorder
CN113171351A (zh) * 2021-04-02 2021-07-27 海南锦瑞制药有限公司 一种盐酸地尔硫卓控释丸剂及其制备方法
CA3218884A1 (en) 2021-05-11 2022-11-17 David Nutt Therapeutic aminoindane compounds and compositions
IL309073A (en) 2021-06-03 2024-02-01 Arcadia Medicine Inc Enantiomeric entactogen compounds and methods of their use.
AU2022325861A1 (en) 2021-08-11 2024-02-29 Biomea Fusion, Inc. Covalent inhibitors of menin-mll interaction for diabetes mellitus
WO2023027966A1 (en) 2021-08-24 2023-03-02 Biomea Fusion, Inc. Pyrazine compounds as irreversible inhibitors of flt3
WO2023039240A1 (en) 2021-09-13 2023-03-16 Biomea Fusion, Inc. IRREVERSIBLE INHIBITORS OF KRas
WO2023086341A1 (en) 2021-11-09 2023-05-19 Biomea Fusion, Inc. Inhibitors of kras
US11945785B2 (en) 2021-12-30 2024-04-02 Biomea Fusion, Inc. Pyrazine compounds as inhibitors of FLT3
WO2023139163A1 (en) 2022-01-19 2023-07-27 Awakn Ls Europe Holdings Limited 1,3-benzodioxole esters and their therapeutic use
WO2023156565A1 (en) 2022-02-16 2023-08-24 Awakn Ls Europe Holdings Limited Bridged ring compounds and their therapeutic use as cns agents
WO2023235618A1 (en) 2022-06-03 2023-12-07 Biomea Fusion, Inc. Fused pyrimidine compounds as inhibitors of menin

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL52914C (es) * 1937-11-24
US3247066A (en) * 1962-09-12 1966-04-19 Parke Davis & Co Controlled release dosage form containing water-swellable beadlet
US4177256A (en) * 1973-04-25 1979-12-04 Alza Corporation Osmotic bursting drug delivery device
US4851229A (en) * 1983-12-01 1989-07-25 Alza Corporation Composition comprising a therapeutic agent and a modulating agent
US4917899A (en) * 1983-12-22 1990-04-17 Elan Corporation Plc Controlled absorption diltiazem formulation
US5002776A (en) * 1983-12-22 1991-03-26 Elan Corporation, Plc Controlled absorption diltiazem formulations
US4894240A (en) * 1983-12-22 1990-01-16 Elan Corporation Plc Controlled absorption diltiazem formulation for once-daily administration
GB8518301D0 (en) * 1985-07-19 1985-08-29 Fujisawa Pharmaceutical Co Hydrodynamically explosive systems
JPH0778017B2 (ja) * 1985-12-28 1995-08-23 住友製薬株式会社 パルス的かつ持続放出性製剤
US5336504A (en) * 1987-10-16 1994-08-09 Elan Corporation, Plc Diltiazem formulations and methods of treatment
FR2624732B1 (fr) * 1987-12-21 1991-02-15 Synthelabo Formulation pharmaceutique a liberation prolongee
US5000962A (en) * 1989-08-25 1991-03-19 Schering Corporation Long acting diltiazem formulation
DK469989D0 (da) * 1989-09-22 1989-09-22 Bukh Meditec Farmaceutisk praeparat
US5017381A (en) * 1990-05-02 1991-05-21 Alza Corporation Multi-unit pulsatile delivery system
US5286497A (en) * 1991-05-20 1994-02-15 Carderm Capital L.P. Diltiazem formulation

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8858960B2 (en) 2004-11-19 2014-10-14 GlaxoSmithKline, LLC Method of producing a pharmaceutical product
US8372225B2 (en) 2005-11-18 2013-02-12 Glaxo Group Limited Machine and method for pharmaceutical and pharmaceutical-like product assembly
US9187192B2 (en) 2005-11-18 2015-11-17 Glaxo Group Limited Machine and method for pharmaceutical and pharmaceutical-like product assembly

Also Published As

Publication number Publication date
AU4643493A (en) 1995-01-03
DE69331806T2 (de) 2003-01-16
EP0701437A4 (en) 1996-10-09
EP0701437A1 (en) 1996-03-20
US5260068A (en) 1993-11-09
EP0701437B1 (en) 2002-04-10
JP3877329B2 (ja) 2007-02-07
JPH09500866A (ja) 1997-01-28
AU680620B2 (en) 1997-08-07
WO1994028882A1 (en) 1994-12-22
ATE215818T1 (de) 2002-04-15
US5508040A (en) 1996-04-16
CA2163433A1 (en) 1994-12-22
DE69331806D1 (de) 2002-05-16
CA2163433C (en) 2003-07-08

Similar Documents

Publication Publication Date Title
ES2173891T3 (es) Sistema de liberacion pulsatil de un farmaco multiparticulado.
ATE173159T1 (de) Auf hydroxyethylzellulose basierende oralen arzneidosisformen mit verzoegerter wirkstoffabgabe
Brand et al. Drugs used in motion sickness. A critical review of the methods available for the study of drugs of potential value in its treatment and of the information which has been derived by these methods
NO923756D0 (no) Osmotisk doseringssystem for avgivelse av vaeskeformig medikament
ES488168A0 (es) Proceso para la preparacion de tabletas farmaceuticas o medicinales de administracion oral, con liberacion retardada delagente activo, en tabletas en las que la cantidad de libera-cion del agente activo es predeterminada.
ATE30380T1 (de) Pharmazeutische formulierungen mit mehrfachen einheiten.
DE69330910T2 (de) Arzneiabgabesystem mit stossweiser freisetzung von partikeln
ATE19589T1 (de) Pharmazeutische dreilagen-filmpraeparate mit lang anhaltender wirkung.
MX10086A (es) Un sistema para la administracion de substancias activas no solubles en agua y procedimiento para su preparacion.
MX166703B (es) Preparacion farmaceutica para liberacion sostenida
UY25710A1 (es) Sistema de entrega controlado de droga administrado oralmente, que provee control temporal y espacial
DE69100991T2 (de) Pharmazeutische formulierungen.
FR2395026A1 (fr) Dose medicamenteuse a unites multiples
MX169815B (es) Tableta de medicamento masticable que contiene medios para enmascarar el sabor
ES2010466A6 (es) Formas de administracion solidas, de rapida desintegracion.
SE7711102L (sv) Nya medel och nya sett att behandla klimakteriska bortfallsymptom
Dreiling The Lymphatics, Pancreatic Ascites, and Pancreatic Inflammatory Disease.
ES2097952T3 (es) Comprimidos de liberacion programada que contienen naproxeno.
BR0007513A (pt) Fosfatidilinositóis sulfatados, sua preparação euso
Rubens et al. Difenoxine (R 15403), the active metabolite of diphenoxylate (R 1132). 5. Clinical comparison of difenoxine and diphenoxylate in volunteers and in patients with chronic diarrhea. Double-blind cross-over assessments
ES2043567T1 (es) Una composicion farmaceutica de liberacion controlada para uso oral que contiene farmacos anti-inflamatorios no esteroideos.
NO930032L (no) Doseringsform for administrering av et medikament for aa frembringe circadian terapi
IT1271447B (it) Complesso di vaccinazione contro la malattia emorragica virale del coniglio e vaccini confezionati in modo da essere utilizzati in questo complesso
GT200000187A (es) Un estuche de combinacion usado en el tratamiento del paludismo.
TH3407EX (th) อุปกรณ์จ่ายยา

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 701437

Country of ref document: ES